Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 6Leukemia, Lymphocytic, Chronic, B-Cell 4Prostatic Neoplasms 3Lymphoma, Follicular 3Small Cell Lung Carcinoma 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Carcinoma, Non-Small-Cell Lung 2Waldenstrom Macroglobulinemia 1Squamous Cell Carcinoma of Head and Neck 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Locally Advanced Esophageal or GE Junction Cancer 1Laryngeal Neoplasms 1Hormone Refractory Prostate Cancer 1Gliosarcoma 1Glioblastoma 1Extensive Stage Small Cell Lung Cancer 1Disease 1Burkitt Lymphoma 1Brain Neoplasms 1Adrenocortical Carcinoma 1

Interventions

Docetaxel 4radium Ra 223 dichloride 2Prednisone 2sargramostim 1gossypol acetic acid 1epothilone B 1cabazitaxel 1bafetinib 1Sunitinib 1PE regimen 1Mycobacterium w vaccine 1Interleukin-2 1Injections 1Everolimus 1Etoposide 1Denosumab 1Cyclophosphamide 1Cisplatin 1Carboplatin 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hormone Refractory Prostate Cancer × gossypol acetic acid × Clear all
NCT00286806 2010-08-24

A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer

Ascenta Therapeutics

Phase 1/2 Completed
27 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡